Sentences with phrase «tumor patients treated»

In general, brain tumor patients treated with radiation therapy tolerate treatment extremely well.

The percentage of Hodgkin lymphoma and Wilms tumor patients treated with radiation fell from 96 to 77 percent and 77 to 49 percent respectively.

Not exact matches

It will focus its initial clinical sequencing efforts on cancer, teaming up with the Moores Cancer Center at the University of California, San Diego to sequence the genomes of every patient who is treated there, as well as perform a full genome sequence on their tumors.

This method, sometimes called «liquid biopsy,» can provide guidance for treatment decisions, monitoring of cancer therapy, and organism - wide screening for the presence of nascent metastatic tumors in drug - treated cancer patients.

Finding individual differences in tumors is key to treating the right patient with the right medicine at the right time, researchers say

Steven Rosenberg, chief of surgery at NCI, riveted everyone's attention by recounting the varied success of treating patients with tumor - infiltrating lymphocytes and then took a few moments to address audience members about advancing their scientific careers.

«We treated these three patients with drugs that attack these genetic alterations and saw tumor shrinkage.

In a recent study, working with a team of researchers, Danino demonstrated that bacteria in pancreatic tumors degrade a chemotherapy drug — Gemcitabine — most commonly used to treat patients who have pancreatic cancer.

In particular, the study suggests that two miRNAs — miR - 4516 and miR - 601 — in tumor cells along with Gleason score and lymph node status may help identify patients who might experience rising PSA after they've been treated with radiation therapy.

«We now hope to design larger clinical studies to treat patients» tumors harboring these novel genomic aberrations to further explore the precise extent of clinical benefit for patients with primary or advanced cholangiocarcinoma.»

If hypofractionated radiation with curative intent can reduce the treatment time for lung cancer patients by half with no greater toxicity, and with equivalent — if not better — tumor control and survival outcomes, this research could result in a change in the paradigm of how a large subset of locally advanced NSCLC patients are treated.»

However, from their experience in treating patients with brain tumors, Dr. Hawasli and coauthors raise concerns about this recommendation.

Human tumor cells (red) growing in a zebrafish embryo may help doctors choose how to treat cancer patients.

Researchers elsewhere have been testing metformin in pancreatic cancer patients with little success, says Le, despite indications that it's a good candidate to treat glucose - dependent tumors.

Using tumor biopsies from BRAF melanoma patients treated with either BRAF inhibitors or with combined BRAF and MEK inhibitors, a recently FDA - approved drug combination to fight the other mechanisms of resistance, the researchers found that tumors resistant to the BRAF inhibitors had increased levels of autophagy compared with baseline tumors.

«In upcoming decades, an increasing proportion of breast cancer patients will be elderly and, therefore, the additional costs of treating over-diagnosed tumors could result in a tremendous increase in health expenditure, while no actual health benefits are being obtained.

Among patients with non-small cell lung cancer (NSCLC) fueled by ALK gene alterations who were being treated with crizotinib (Xalkori), a decrease in the number of circulating tumor cells (CTCs) harboring increased copies of the ALK gene over the first two months of treatment was associated with increased progression - free survival.

«If, as we postulate, the combination of chemotherapy and PARP inhibition is successful in treating patients with HRD tumors, I expect that others will start exploring whether similar drugs or analogous therapies can make a difference in these diseases,» Heeke concludes.

This study of 37 patients (24 men and 13 women, ages 51 to 80) who have never been treated with chemotherapy found direct correlation of the amount of cfDNA with tumor metabolism (based on PET - derived parameters), but not with metabolic tumor volume.

Forty - nine percent of patients treated with selumetinib exhibited tumor regression, compared with none in the chemotherapy group.

Sharma had developed a new method for studying how tumors with different characteristics respond to different immunotherapies: She would treat patients before their growths were surgically removed, then analyze the tissue in her lab.

In Cohort A, pembrolizumab shrunk tumors by more than 30 percent in eight of 170 patients, or five percent, and stabilized the disease in 35, or 21 percent, of those previously treated for mTNBC.

To see if PGD and the pentose phosphate pathway were tied to the epigenetic changes the researchers had detected in distant metastases, they treated tumor cells from different sites in a single patient with the drug 6 - aminonicotinamide (6AN), which is known to inhibit PGD but is not used in humans because of its severe side effects.

A 2013 paper in the same journal reported excellent vocal outcomes for the first 92 treated patients, but neither paper included the kind of follow - up data required to confirm the treatment's long - term effectiveness in curing the tumors.

Of the 82 treated patients with small tumors, 96 percent (79 of 82) have had no recurrence more than three years after treatment, and 80 percent (28 of 35) of those with mid-size tumors also have had no recurrence.

«We used biopsied tumor samples from DIPG patients to create models in the lab, which we studied and then used to test a novel, targeted approach to treating the tumor.

A Mayo Clinic study is shedding light on why some rheumatoid arthritis patients respond poorly when treated with tumor necrosis factor inhibitors, part of a class of drugs called biologics.

Of the several thousand cancer patients treated annually at the Heidelberg National Center for Tumor Diseases (NCT), whole - genome sequencing of tumors is offered to all patients who might benefit, says Eils.

A section of a tumor organoid grown from cells derived from a patient with high - grade serous ovarian cancer (left) and a mini-tumor treated with ReACp53, resulting in extensive cancer cell death.

You have to treat each patient's tumor cells individually,» he adds.

The findings could lead to future investigation into potential new ways to treat and monitor breast cancer by looking outside the tumor and exploiting the patient's systemic immune system response.

The approach regularly results in patients entering treatment pathways with potential negative side effects, to treat low - risk tumors.

In their research, scientists at Rutgers created animal models that closely resemble the cancerous tumors found in women with ovarian cancer by injecting tumor tissues obtained from gynecological cancer patients treated at the Cancer Institute into laboratory mice.

«Cancers evade immunotherapy by «discarding the evidence» of tumor - specific mutations: Discovery could explain widespread acquired resistance among patients treated with immune checkpoint blockade drugs.»

An important approach in advanced cancer medicine is to treat cancer using a patient's immune cells after first arming the cells against the tumor in culture.

Image guided radiation therapy (IGRT) is a commonly used modality to ensure treatment accuracy in the management of pediatric tumors; however, consensus recommendations are needed in order to guide clinical decisions on the use of IGRT in treating pediatric patients, according to a study published in the September - October 2014 issue of Practical Radiation Oncology (PRO), the official clinical practice journal of the American Society for Radiation Oncology (ASTRO).

Chimeric antigen receptor (CAR) T cell therapy, which edits a cancer patient's T cells to recognize their tumors, has successfully helped patients with aggressive blood cancers but has yet to show the ability to treat solid tumors.

Oncologists have long known that in rare cases, after patients receive radiation therapy to shrink a tumor, the immune system will mount an aggressive response that wipes out not only the tumor, but metastases throughout the body that hadn't been treated with the radiation.

Results of a phase one trial show that an investigational topical drug, resiquimod gel, causes regression of both treated and untreated tumor lesions and may completely remove cancerous cells from both sites in patients with early stage cutaneous T cell lymphoma (CTCL)-- a rare type of non-Hodgkin lymphoma that affects the skin.

In early clinical trials, Sessler and his colleagues treated 39 metastatic brain tumor patients with texaphyrins 2 hours before radiation therapy for 10 days.

For patients with difficult - to - treat cancers, doctors increasingly rely on genomic testing of tumors to identify errors in the DNA that indicate a tumor can be targeted by existing therapies.

To search for other characteristics of ccRCC tumors that influences immunotherapy response or resistance, the researchers used whole - exome DNA sequencing to analyze tumor samples from 35 patients treated in a clinical trial with the checkpoint blocker nivolumab (Opdivo).

A doctor treating a patient with a potentially fatal metastatic breast tumor would be very pleased to find, after administering a round of treatment, that the primary tumor had undergone a change in character — from aggressive to static, and no longer shedding cells that can colonize distant organs of the body.

For this study the authors studied tumor samples from 111 patients treated at the Instituto Nacional de Enfermedades Neoplásicas (INEN), in Lima, Perú.

Many tumor patients are consequently treated with chemotherapy after surgery to fight metastasis.

Historically, medulloblastoma has been treated as a single disease even though researchers at St. Jude and elsewhere showed that patient outcomes vary widely based on their tumor subtype.

A total of seven patients went on to have primary tumors surgically removed, and another patient was treated with peptide receptor radionuclide therapy.

«Mesothelioma, a tumor that is caused by asbestos exposure, has been extremely hard to treat; and patients usually survive only 12 to 18 month after diagnosis,» says Mark Poznansky, MD, PhD, director of the MGH - VIC and senior author of the report.

Patients with recurrent glioblastoma multiforme (GBM) treated with an experimental vaccine made from the patient's own resected tumor tissue showed an improved survival compared with historical patients who received the standard of care alone, according to an analysis of a phase 2 trial of this vaccine that was recently published in the journal Neuro - Oncology and accompanied by an editorial highlighting the importance of thPatients with recurrent glioblastoma multiforme (GBM) treated with an experimental vaccine made from the patient's own resected tumor tissue showed an improved survival compared with historical patients who received the standard of care alone, according to an analysis of a phase 2 trial of this vaccine that was recently published in the journal Neuro - Oncology and accompanied by an editorial highlighting the importance of thpatients who received the standard of care alone, according to an analysis of a phase 2 trial of this vaccine that was recently published in the journal Neuro - Oncology and accompanied by an editorial highlighting the importance of the trial.

• A patient's undifferentiated small bowel sarcoma was found to contain a KIT gene deletion, resulting in a revised diagnosis of GIST (gastrointestinal stromal tumor) that was successfully treated with imatinib.